Sugi Predict

Sugi Predict / Compounds / Desmethylflurbiprofen

Desmethylflurbiprofen

Desmethylflurbiprofen

SCHEMBL239447

C.O=C(O)Cc1ccc(-c2ccccc2)c(F)c1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 4/20 0.55
▸ LMNA P02545 2/20 0.55
▸ TSHR P16473 2/20 0.55
▸ ABCC4 O15439 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ DGAT1 O75907 2/20 0.53
▸ SOAT1 P35610 2/20 0.53
▸ PSEN1 P49768 2/20 0.51
▸ PSEN2 P49810 2/20 0.51
▸ APH1B Q8WW43 2/20 0.51
▸ NCSTN Q92542 2/20 0.51
▸ APH1A Q96BI3 2/20 0.51
▸ PSENEN Q9NZ42 2/20 0.51
▸ PTGS2 P35354 3/20 0.50
▸ FAAH O00519 1/20 0.50
▸ CDK2 P24941 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ FABP2 P12104 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desmethylflurbiprofen SCHEMBL538938 0.98 PTGS1 (0.56) PTGS1LMNATSHRABCC4GAA
Methane SCHEMBL11691361 0.87 CA2 (0.55) PTGS1LMNATSHRABCC4GAA
SCHEMBL7562017 0.85 PTGS1 (0.51) PTGS1LMNATSHRDGAT1SOAT1
SCHEMBL4943055 0.85 CA2 (0.56) PTGS1LMNATSHRABCC4GAA
SCHEMBL11726632 0.85 SRD5A2 (0.49) PTGS1LMNATSHRABCC4GAA
SCHEMBL15564003 0.84 AKR1C3 (0.56) PTGS1LMNATSHRABCC4GAA
Methane SCHEMBL9085715 0.83 HPGD (0.51) PTGS1LMNATSHRGAAPSEN1
Methane SCHEMBL11689551 0.83 GAA (0.49) PTGS1LMNATSHRABCC4GAA
SCHEMBL9342620 0.83 CDK2 (0.46) PTGS1LMNATSHRDGAT1SOAT1
SCHEMBL3839814 0.82 PSEN1 (0.66) PTGS1LMNATSHRABCC4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028600-A Trans perovskite solar cell with fluorine-containing salt interface modification layer and preparation method thereof 景德镇陶瓷大学 2026-05-12 — — CN claimed
US-20200224159-A1 UNIFIED CELL DIFFERENTIATION PROTOCOL EYESTEM RESEARCH PRIVATE LIMITED (IN) 2020-07-16 — — US claimed
EP-1725222-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS Pharmacia Corporation (US) 2006-11-29 — — EP claimed
EP-1608351-B1 COMPOSITIONS CONTAINING SUPEROXIDE DISMUTASE AND A SELECTED ET 5-LIPOXYGENASE INHIBITOR AND USES THEREOF ISOCELL S A (FR) 2006-09-06 — — EP claimed
EP-1691797-A2 COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD Pharmacia Corporation (US) 2006-08-23 — — EP claimed
US-20060154954-A1 Combinations and use of selected pharmaceutically active compounds ALTANA PHARMA AG (DE) 2006-07-13 — — US claimed
CN-1747731-A Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders ALTANA PHARMA AG (DE) 2006-03-15 — — CN claimed
US-20060034941-A1 Organ preconditioning, arrest, protection, preservation and recovery GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) 2006-02-16 — — US claimed
EP-1599175-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA Pharma AG (DE) 2005-11-30 — — EP claimed
WO-2005084654-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS PHARMACIA CORPORATION (US) 2005-09-15 — — WO claimed
US-20040242597-A1 Combination NYCOMED GMBH (DE) 2004-12-02 — — US claimed
WO-2004071391-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA PHARMA AG (DE) 2004-08-26 — — WO claimed
US-20040147581-A1 Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy PHARMACIA CORPORATION (US) 2004-07-29 — — US claimed
WO-2004056181-A1 ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) 2004-07-08 — — WO claimed
WO-2004056180-A1 ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) 2004-07-08 — — WO claimed
EP-1429807-A2 COMBINATION OF A NSAID AND A PDE-4 INHIBITOR ALTANA Pharma AG (DE) 2004-06-23 — — EP claimed
WO-2004045509-A2 METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY PHARMACIA CORPORATION (US) 2004-06-03 — — WO claimed
WO-2004000273-A1 ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY NICOX S.A. (FR) 2003-12-31 — — WO claimed
WO-2003024489-A2 COMBINATION OF A NSAID AND A PDE-4 INHIBITOR ALTANA PHARMA AG (DE) 2003-03-27 — — WO claimed
WO-2002092072-A2 DRUGS FOR THE TREATMENT OF THE ALZHEIMER DISEASE NICOX S.A. (FR) 2002-11-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147581-A1 Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy HTR2A, HTR1A, TPH2 PTGS1 27/4885LMNA 3410/4885TSHR 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.